Foghorn Therapeutics
FHTX
45 hedge funds and large institutions have $307M invested in Foghorn Therapeutics in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
1.69% less ownership
Funds ownership: 65.03% → 63.34% (-1.7%)
4% less funds holding
Funds holding: 47 → 45 (-2)
35% less capital invested
Capital invested by funds: $470M → $307M (-$163M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.75M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.57M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.79M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$1.13M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$232K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.93M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$2.86M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$2.09M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$1.26M |
| 5 |
Millennium Management
New York
|
-$864K |
FHTX Hedge Fund Activity: Q1 2021 in Review
45 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q1 2021, worth a combined $307M — down 35% from $470M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of FHTX and 3 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 12 added.
The largest buyer was Morgan Stanley, adding an estimated $5.75M. The largest seller was BlackRock, cutting an estimated $3.93M.
- 45 institutional investors held Foghorn Therapeutics (FHTX) as of Q1 2021, down from 47 in Q4 2020.
- Funds reported $307M of Foghorn Therapeutics stock for Q1 2021, down 35% quarter-over-quarter.
- 3 funds opened new Foghorn Therapeutics positions in Q1 2021 and 5 closed out, a net change of -2 holders.
- The largest Foghorn Therapeutics buyer in Q1 2021 was Morgan Stanley, an estimated $5.75M added.
- The largest Foghorn Therapeutics seller in Q1 2021 was BlackRock, an estimated $3.93M sold.
Based on aggregated 13F filings for Q1 2021.